The Kick-off Symposium for the Cluster for Regenerative Medicine in Tonomachi Haneda(CREME TONOHANE) was held at Shimadzu Tokyo Innovation Plaza on Wednesday, September 26, 2024.
The following speakers took part in the symposium, commemorative lectures, and panel discussion.
Hideyuki Okano
Director, Keio University Regenerative Medicine Research Center (KRM) Shigeto Shimmura Director, Fujita Health University Haneda Clinic Head, Department of Clinical Regenerative Medicine, School of Medicine, Fujita Health University Kazunori Kataoka Center Director, Kawasaki Institute of Industrial Promotion, Innovation Center of NanoMedicine (iCONM) Ryuta Nomura Chairman, Central Institute for Experimental Medicine and Life Science (CIEM) Makoto Suematsu Research Director, Central Institute for Experimental Medicine and Life Science (CIEM) Yasuda Satoshi (Facilitator) Director, Division of Cell-based Therapeutic Products, National Institute of Health Sciences (NIHS) Reina Kodera Deputy Director, Bio-Industry Division, Commerce and Information Policy Bureau, Ministry of Economy, Trade and Industry (METI) Shin Kawamata CEO, Cyto-Facto Inc.
Jun Kawai
Part-time researcher, Next-Gen Life Science Technology Development Project, Kanagawa Institute of Industrial Science and Technology (KISTEC) Yasunori Aizawa Associate Professor, Science Tokyo (School of Life Science and Technology) Kenichi Harada Representative Director, Regenerative medicine & cell therapy Industrialization Network of Kanagawa (RINK)
※CREME TONOHANE was created as a platform to accelerate the real-world application and global development of regenerative medicine and cell therapy. It is located in the central area between Tonomachi District, Kawasaki City, in Kanagawa Prefecture, and Haneda District in Ota Ward of Tokyo. As a hub for regenerative medicine in eastern Japan, CREME TONOHANE aims to advance research and development by bringing together universities, corporations, and public research institutions. The cluster has also been selected as an indirect recipient of the METI（Ministry of Economy, Trade and Industry）’s “Research Grant for Projects that Develop an Environment Conducive for Social Implementation of Regenerative Medicine, Cell and Gene Therapy” under the supplementary budget for FY 2022.
With cell samples provided from hospitals, including the Keio University Hospital, research institutions at Tonomachi and Haneda conduct quality analysis and standardization to establish a set of scientific criteria for the evaluation of cells. Based on these criteria, cells for regenerative medicine products will be manufactured, with the ultimate goal of providing regenerative medicine treatment at the Fujita Health University Haneda Clinic and the Keio University Hospital.
